First identification of an Escherichia coli clinical isolate producing both metallo-beta-lactamase VIM-2 and extended-spectrum beta-lactamase IBC-1.

Published

Journal Article

An Escherichia coli strain with decreased susceptibility to carbapenems was isolated from a hospitalised patient in Athens, Greece. The strain was resistant to all beta-lactams, including aztreonam, whereas the MIC of imipenem and meropenem was 0.5 mg/L. A positive EDTA-disk synergy test suggested the production of a metallo-beta-lactamase. PCR experiments revealed the presence of the bla(VIM-2), bla(IBC-1), and bla(TEM-1) genes. Resistance to beta-lactams was not transferable by conjugation. This is the first report of a clinical isolate of E. coli producing VIM-2, and the first report of the coexistence of bla(VIM-2) and bla(IBC-1) in a single clinical isolate.

Full Text

Cited Authors

  • Galani, I; Souli, M; Chryssouli, Z; Katsala, D; Giamarellou, H

Published Date

  • August 2004

Published In

Volume / Issue

  • 10 / 8

Start / End Page

  • 757 - 760

PubMed ID

  • 15301681

Pubmed Central ID

  • 15301681

Electronic International Standard Serial Number (EISSN)

  • 1469-0691

International Standard Serial Number (ISSN)

  • 1198-743X

Digital Object Identifier (DOI)

  • 10.1111/j.1469-0691.2004.00913.x

Language

  • eng